Rapid advances of immuno-oncology have triggered a new need for tumour models growing in immunocompetent mice.
The syngeneic tumour models were mostly generated by inducing tumours in mice. Each model can develop subcutaneous or orthotopic tumours when implanted in the matching strain of immunocompetent mice.
Our approval for animal experimentation allows us to implant those models in C57BL/6, BALB/c, B6D2F1 and C3H. With a delay of a few weeks, we can obtain the agreement for other mouse strains.
In preclinical immuno-oncology, the syngeneic models are widely used to test combinations with approved Immune-Checkpoint Inhibitors like anti-PD1 or anti-PDL1. Amongst our syngeneic tumour models, we characterised several displaying primary resistances to anti-PD1 and/or anti-PDL1.
Why syngeneic models?
-
A fully functional immune system
Unlike xenograft models, syngeneic models retain the complete host immune system which enables the study of tumour-immune interactions and the evaluation of immunomodulatory compounds under relevant physiological conditions.
-
Immuno-oncology benchmarking
Our syngeneic models are widely used to test combinations with approved immune checkpoint inhibitors (anti-PD-1, anti-PD-L1). Several models have been characterised for their primary resistance to anti-PD-1 and/or anti-PD-L1, complementing our portfolio of secondary resistances.
-
Well-characterised, data-backed models
Over 20 tumour cell lines have been examined for immune infiltration phenotype, TME composition, and responsiveness to SOC therapies. Models are described using historical in-house data, with molecular profiles available for key lines.
Liquid tumours in Syngeneic models
Liquid tumour models in syngeneic hosts use a fully functional imune system. This makes them well suited to studying tumour-immune interactions in haematological malignances.
They are especially useful for testing novel agents, since they reflect disease biology more closely than immunodeficient models.
Antineo provides a range of liquid tumors in syngeneic models, including models for leukemia, myeloma, and lymphoma.
- P388 (Available on request)
- EL4 (Available on request)
- 2PK3 (Available on request)
- L1210 (View PDF)
- L5178Y (On request)
- NFS-60 (Available on request)
Solid tumours in Syngeneic models
Syngeneic solid tumour models can be implanted subcutaneously or orthotopically. They are selected for their relevance to clinical oncology. Each model presents a distinct tumour microenvironment (TME) and provide a meaningful basis for studying immune infiltration, checkpoint inhibitor response, and combination strategies.
Antineo provides a wide variety of syngeneic mice models that have well-characterized responses to genetic assessment (e.g., RNA-seq), immunological profiling using flow cytometry, and known immune checkpoint inhibitors (e.g., anti-PDL-1, anti-PD-1).
Models from our collection include common cancer types including liver, prostate, melanoma, breast, colon, pancreatic and more.
They benefit from a comprehensive understanding of their molecular profiles and are fully described cell models based on historical data. We have examined the immune infiltration phenotype and responsiveness to standard of care (SOC) therapies in over 20 tumor cell lines.